Search research articles
Contact Us
Filters
Showing results (1-10 of 8) with videos related to
Page
of 1
Sort By:
Journal of Hematotherapy
|
December 1, 1995
Bone marrow and clinical gene therapy
G D Schmidt-Wolf, I G Schmidt-Wolf
Immunology Today
|
April 1, 1995
Cytokines and gene therapy
G D Schmidt-Wolf, I G Schmidt-Wolf
Annals of Hematology
|
November 1, 1996
Cancer and gene therapy
G D Schmidt-Wolf, I G Schmidt-Wolf
British Journal of Haematology
|
March 29, 2002
Immunomodulatory gene therapy for haematological malignancies
G D Schmidt-Wolf, I G H Schmidt-Wolf
Clinical and Experimental Medicine
|
May 16, 2003
Gene therapy for hematological malignancies
G D Schmidt-Wolf, I G H Schmidt-Wolf
Annals of Hematology
|
February 1, 1997
Activated T cells and cytokine-induced CD3+CD56+ killer cells
G D Schmidt-Wolf, R S Negrin, I G Schmidt-Wolf
Cancer Immunology, Immunotherapy : CII
|
January 6, 1999
Generation of cytokine-induced killer cells using exogenous interleukin-2, -7 or -12
B Zoll, P Lefterova, M Csipai, et al.
Annals of Hematology
|
July 8, 2003
Joint HOVON-50/GMMG-HD3 randomized trial on the effect of thalidomide as part of a high-dose therapy regimen and as maintenance treatment for newly diagnosed myeloma patients
H Goldschmidt, P Sonneveld, F W Cremer, et al.
Page
of 1
Search research articles
Search
Showing results (1-10 of 8) with videos related to
Sort By:
Page
of 1
Journal of Hematotherapy
|
December 1, 1995
Bone marrow and clinical gene therapy
G D Schmidt-Wolf, I G Schmidt-Wolf
Immunology Today
|
April 1, 1995
Cytokines and gene therapy
G D Schmidt-Wolf, I G Schmidt-Wolf
Annals of Hematology
|
November 1, 1996
Cancer and gene therapy
G D Schmidt-Wolf, I G Schmidt-Wolf
British Journal of Haematology
|
March 29, 2002
Immunomodulatory gene therapy for haematological malignancies
G D Schmidt-Wolf, I G H Schmidt-Wolf
Clinical and Experimental Medicine
|
May 16, 2003
Gene therapy for hematological malignancies
G D Schmidt-Wolf, I G H Schmidt-Wolf
Annals of Hematology
|
February 1, 1997
Activated T cells and cytokine-induced CD3+CD56+ killer cells
G D Schmidt-Wolf, R S Negrin, I G Schmidt-Wolf
Cancer Immunology, Immunotherapy : CII
|
January 6, 1999
Generation of cytokine-induced killer cells using exogenous interleukin-2, -7 or -12
B Zoll, P Lefterova, M Csipai, et al.
Annals of Hematology
|
July 8, 2003
Joint HOVON-50/GMMG-HD3 randomized trial on the effect of thalidomide as part of a high-dose therapy regimen and as maintenance treatment for newly diagnosed myeloma patients
H Goldschmidt, P Sonneveld, F W Cremer, et al.
Page
of 1